Clinical trials: Liver Diseases, Alcoholic
NASH, Cirrhosis, Liver
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical…
- Trial name
- NCT05500222
- Testing
- Resmetirom
- Where
- 141 sites in United States, Belgium and 7 more
- Volunteers
- 845 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Steatohepatitis, Nonalcoholic
Formula Diet Treatment for NASH Patients.
Non-alcoholic steatohepatitis (NASH) - also called fatty liver - is medically a serious problem because the liver tissue becomes fatty and stiff, and inflammatory reactions occur.
- Trial name
- NASH (NCT04707651)
- Testing
- Formula diet
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- West German Center of Diabetes and Health
NAFLD
Polyunsaturated Fatty Acids in Patients With NAFLD.
Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months.
- Trial name
- NCT02647294
- Testing
- Maxicor
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- General University Hospital, Prague
Type 2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This prospective, open-label, randomized clinical study will evaluate the effect of empagliflozin 10 mg daily, added to standard T2DM treatment, on liver fat and hepatic parameters in adults with type 2 diabetes and nonalcoholic…
- Trial name
- EMPA-LIVER (NCT07915596)
- Testing
- Empagliflozin 10/15 mg administered orally once daily in addition to standard treatment for type 2 diabetes mellitus.
- Where
- Bangladesh
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Non Alcoholic Steatohepatitis
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01766713
- Testing
- Ezetimibe
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Nonalcoholic Fatty Liver Disease (NAFLD)
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease
This study will advance several goals of the NIH Action Plan: 1) establish a multidisciplinary team to develop quantitative methodologies and imaging protocols for liver, 2) validate diagnostic criteria and methodologies for…
- Trial name
- NCT01930123
- Testing
- intravenous fructose challenge, Blood Draw
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Manal F Abdelmalek
Nonalcoholic Steatohepatitis
Predictable MR Index for Nonalcoholic Steatohepatitis (NASH)
1. To evaluate feasibility of using multiparametric Magnetic resonance(MR) imaging to predict nonalcoholic steatohepatitis(NASH) 2.
- Trial name
- NCT03375008
- Testing
- Imaging diagnostic and biopsy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Korea University Guro Hospital
Non-Alcoholic Fatty Liver Disease
Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment.
- Trial name
- NCT06735118
- Testing
- Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yunnan Cancer Hospital
NAFLD, NASH
The European NAFLD Registry
The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and…
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT04442334
- Where
- 37 sites in Belgium, Finland and 10 more
- Volunteers
- 10,000 people
- Sponsor
- Newcastle University
Non-alcoholic Fatty Liver Disease
Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
This study design to examine performance of trigonella foenum-graecum (TFG) in treatment of non-alcoholic fatty liver disease. Base on inclusion and exclusion criteria, 50 patients select and then randomize into intervention and…
- Trial name
- NCT02303314
- Testing
- Trigonella Foenum-graecum Seed Extract
- Where
- Iran
- Volunteers
- 35 people
- Sponsor
- Shiraz University of Medical Sciences
Alcoholic Hepatitis
G-CSF Plus NAC In Severe Alcoholic Hepatitis
Alcoholic hepatitis is related to very high mortality rate. About 40% of the patients are died within first 6 months after the detection of the clinical syndrome.
- Trial name
- NCT02971306
- Testing
- standard medical therapy, G-CSF, n-Acetylcysteine
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Alcoholism, Alcohol Use Disorder
Impact of Integrating an Addiction Team on Post Liver Transplantation Survival for Alcohol-related Liver Disease and Its Complications.
Investigator seeks to determine wether integrating an addiction team into a liver transplantation unit improves the prognosis of patients with alcohol-related liver disease requiring liver transplantation.
- Conditions
- Alcoholism, Alcohol Use Disorder, Alcohol; Liver
- Trial name
- NCT04964687
- Testing
- Liver transplantation
- Where
- France
- Volunteers
- 616 people
- Sponsor
- University Hospital, Montpellier
Cardiovascular Disease
The Impact of Almond Nut Consumption on Markers of CVD & Metabolic Health
The purpose of this study is to investigate the cardio-metabolic health effects of consuming almond nuts in place of habitual (usual) snack products in adults at moderate risk of developing cardiovascular disease
- Trial name
- Almonds (NCT02907684)
- Testing
- Almonds, Muffins/Crackers
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- King's College London
Nonalcoholic Fatty Liver Disease
Dietary Treatment Study of Pediatric NAFLD
This is an investigator initiated study being conducted in equal numbers at two sites, University of California, San Diego (UC San Diego) and Emory University (EU).
- Trial name
- DTS (NCT02513121)
- Testing
- Dietary modification
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
NAFLD, Insulin Resistance
Determination of Insulin-stimulated Hepatic Glucose Uptake by PET-CT Measurements
In the absence of excessive alcohol consumption, increased levels of fat in the liver (>5%) are diagnosed as non-alcoholic fatty liver (NAFL).
- Conditions
- NAFLD, Insulin Resistance, Overweight and Obesity
- Trial name
- ISGU (NCT04938544)
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
NAFLD
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity which can progress to deadly complications like end-stage liver disease and hepatocellular carcinoma.
- Trial name
- NCT04861571
- Testing
- Dietary intervention with very low calorie diet (VLCD), Control Arm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Overweight or Obesity
Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition
Soybean peptides are a mixture of active peptides obtained from the hydrolysis of soybean protein, which have biological activities such as antioxidant, blood pressure lowering, anti-fatigue and lipid lowering, etc.
- Trial name
- NCT04728399
- Testing
- Experimental group, Control group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fangfang Zeng
NAFLD
NAFLD in Patient of Hypothyroidism
Nonalcoholic fatty liver disease (NAFLD) is the most important chronic liver disease in the western world, affecting almost 30% of the general population.
- Trial name
- NCT05813301
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-alcoholic Fatty Liver Disease
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis.
- Trial name
- NCT02875392
- Testing
- 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
- Where
- Taiwan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Cardiovascular Diseases, Lipid Disorder
SRMA of the Effect of Soy Milk vs Cow's Milk on Cardiometabolic Outcomes
Dairy consumption has shown associations with decreased incidence of cardiometabolic diseases. With the growing interest in plant-based eating, and the mounting evidence for the cardiovascular benefits of plant forward diets…
- Conditions
- Cardiovascular Diseases, Lipid Disorder, Metabolic Disease, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05637866
- Testing
- Soy milk
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.